{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:11:12Z","timestamp":1794892272345,"version":"4.9.1"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["R01 HS024277-01A1"],"award-info":[{"award-number":["R01 HS024277-01A1"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["K08 HS025026"],"award-info":[{"award-number":["K08 HS025026"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,26]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>For patients at risk for multidrug-resistant organisms, IDSA\/ATS guidelines recommend empiric therapy against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas. Following negative cultures, the guidelines recommend antimicrobial de-escalation. We assessed antibiotic de-escalation practices across hospitals and their associations with outcomes in hospitalized patients with pneumonia with negative cultures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We included adults admitted with pneumonia in 2010\u20132015 to 164 US hospitals if they had negative blood and\/or respiratory cultures and received both anti-MRSA and antipseudomonal agents other than quinolones. De-escalation was defined as stopping both empiric drugs on day 4 while continuing another antibiotic. Patients were propensity adjusted for de-escalation and compared on in-hospital 14-day mortality, late deterioration (ICU transfer), length-of-stay (LOS), and costs. We also compared adjusted outcomes across hospital de-escalation rate quartiles.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 14 170 patients, 1924 (13%) had both initial empiric drugs stopped by hospital day 4. Hospital de-escalation rates ranged from 2\u201335% and hospital de-escalation rate quartile was not significantly associated with outcomes. At hospitals in the top quartile of de-escalation, even among patients at lowest risk for mortality, the de-escalation rates were &amp;lt;50%. In propensity-adjusted analysis, patients with de-escalation had lower odds of subsequent transfer to ICU (adjusted odds ratio, .38; 95% CI, .18\u2013.79), LOS (adjusted ratio of means, .76; .75\u2013.78), and costs (.74; .72\u2013.76).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A minority of eligible patients with pneumonia had antibiotics de-escalated by hospital day 4 following negative cultures and de-escalation rates varied widely between hospitals. To adhere to recent guidelines will require substantial changes in practice.<\/jats:p><\/jats:sec>","DOI":"10.1093\/cid\/ciaa212","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T20:15:53Z","timestamp":1582834553000},"page":"1314-1322","source":"Crossref","is-referenced-by-count":40,"title":["De-escalation of Empiric Antibiotics Following Negative Cultures in Hospitalized Patients With Pneumonia: Rates and Outcomes"],"prefix":"10.1093","volume":"72","author":[{"given":"Abhishek","family":"Deshpande","sequence":"first","affiliation":[{"name":"Center for Value-Based Care Research, Cleveland Clinic Community Care, Cleveland Clinic, Cleveland, Ohio, USA"},{"name":"Department of Infectious Diseases, Respiratory Institute, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra S","family":"Richter","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Pathology Institute, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Haessler","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Massachusetts Medical School\u2013Baystate, Springfield, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter K","family":"Lindenauer","sequence":"additional","affiliation":[{"name":"Institute for Healthcare Delivery and Population Science and Department of Medicine, University of Massachusetts Medical School\u2013Baystate, Springfield, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Chun","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7266-9761","authenticated-orcid":false,"given":"Marya D","family":"Zilberberg","sequence":"additional","affiliation":[{"name":"University of Massachusetts, Amherst, Massachusetts, USA"},{"name":"EviMed Research Group, LLC, Goshen, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B","family":"Imrey","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA"},{"name":"Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Higgins","sequence":"additional","affiliation":[{"name":"Center for Case Management, Natick, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B","family":"Rothberg","sequence":"additional","affiliation":[{"name":"Center for Value-Based Care Research, Cleveland Clinic Community Care, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,3,4]]},"reference":[{"key":"2021042615342625900_CIT0001","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2021042615342625900_CIT0002","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia","volume":"171","author":"American Thoracic Society; Infectious Diseases Society of America","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"2021042615342625900_CIT0003","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2021042615342625900_CIT0004","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1513\/AnnalsATS.201606-486BC","article-title":"Broad- versus narrow-spectrum oral antibiotic transition and outcomes in health care-associated pneumonia","volume":"14","author":"Buckel","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"2021042615342625900_CIT0005","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/jac\/dkv338","article-title":"Antimicrobial de-escalation of treatment for healthcare-associated pneumonia within the Veterans Healthcare Administration","volume":"71","author":"Madaras-Kelly","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2021042615342625900_CIT0006","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s15010-010-0042-z","article-title":"Practice patterns for antibiotic de-escalation in culture-negative healthcare-associated pneumonia","volume":"38","author":"Schlueter","year":"2010","journal-title":"Infection"},{"key":"2021042615342625900_CIT0007","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/S1473-3099(14)70952-1","article-title":"Assessment of empirical antibiotic therapy optimisation in six hospitals: an observational cohort study","volume":"14","author":"Braykov","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2021042615342625900_CIT0008","doi-asserted-by":"crossref","first-page":"e87382","DOI":"10.1371\/journal.pone.0087382","article-title":"Using highly detailed administrative data to predict pneumonia mortality","volume":"9","author":"Rothberg","year":"2014","journal-title":"PLoS One"},{"key":"2021042615342625900_CIT0009","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"key":"2021042615342625900_CIT0010","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jclinepi.2010.10.004","article-title":"A combined comorbidity score predicted mortality in elderly patients better than existing scores","volume":"64","author":"Gagne","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2021042615342625900_CIT0011","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/00031305.1985.10479383","article-title":"Constructing a control group using multivariate matched sampling methods that incorporate the propensity score","volume":"39","author":"Rosenbaum","year":"1985","journal-title":"Am Stat"},{"key":"2021042615342625900_CIT0012","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"2021042615342625900_CIT0013","article-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2019"},{"key":"2021042615342625900_CIT0014","article-title":"GBM Developers. gbm:generalized boosted regression models","author":"Greenwell","journal-title":"R package version 2.1.5"},{"key":"2021042615342625900_CIT0015","volume-title":"Toolkit for weighting and analysis of nonequivalent Groups: a tutorial for the twang package","author":"Ridgeway","year":"2017"},{"key":"2021042615342625900_CIT0016","doi-asserted-by":"crossref","first-page":"ofw244","DOI":"10.1093\/ofid\/ofw244","article-title":"Outcomes associated with antimicrobial de-escalation of treatment for pneumonia within the Veterans Healthcare Administration","volume":"4","author":"Bohan","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2021042615342625900_CIT0017","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.chest.2018.10.014","article-title":"Outcomes associated with de-escalating therapy for methicillin-resistant Staphylococcus aureus in culture-negative nosocomial pneumonia","volume":"155","author":"Cowley","year":"2019","journal-title":"Chest"},{"key":"2021042615342625900_CIT0018","article-title":"Determining the utility of methicillin-resistant Staphylococcus aureus nares screening in antimicrobial stewardsh ip","author":"Mergenhagen","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021042615342625900_CIT0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciy024","article-title":"The clinical utility of methicillin-resistant Staphylococcus aureus (MRSA) nasal screening to rule out MRSA pneumonia: a diagnostic meta-analysis with antimicrobial stewardship implications","volume":"67","author":"Parente","year":"2018","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa212\/33136820\/ciaa212.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/8\/1314\/37391525\/ciaa212.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/8\/1314\/37391525\/ciaa212.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T06:24:34Z","timestamp":1722493474000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/72\/8\/1314\/5780147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,4]]},"references-count":19,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,3,4]]},"published-print":{"date-parts":[[2021,4,26]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa212","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,15]]},"published":{"date-parts":[[2020,3,4]]}}}